中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study

文献类型:期刊论文

作者Bai, X.19; Chen, Y.19; Chen, Y.1,2,3; Liang, X.4; Wang, H.5; Sun, Y.; Chu, Q.7; Pan, Y.8; Cui, J.9; Fang, J.10
刊名ANNALS OF ONCOLOGY
出版日期2024-07-01
卷号35
ISSN号0923-7534
资助项目Innovent Biologics (Suzhou) Co., Ltd.
WOS研究方向Oncology
语种英语
WOS记录号WOS:001301473300002
出版者ELSEVIER
资助机构Innovent Biologics (Suzhou) Co., Ltd.
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/135416]  
专题中国科学院合肥物质科学研究院
作者单位1.Fujian Canc Hosp, VIP Ward, Fuzhou, Peoples R China
2.Fujian Canc Hosp, Dept Clin Nutr, Fuzhou, Peoples R China
3.Fujian Canc Hosp, Canc Bioimmunotherapy Ctr, Fuzhou, Peoples R China
4.Hubei Canc Hosp, Abdominal Med, Wuhan, Peoples R China
5.Hunan Canc Hosp, Chest Radiotherapy Dept 1, Changsha, Peoples R China
6.Shandong First Med Univ, Affiliated Canc Hosp, Phase Clin Res Ctr 1, Shandong Canc Hosp,Shandong Canc Prevent & Treatm, Jinan, Peoples R China
7.Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan, Peoples R China
8.Anhui Prov Hosp, Med Oncol, Hefei, Peoples R China
9.First Hosp Jilin Univ, Oncol, Changchun, Peoples R China
10.Peking Univ, Second Dept Thorac Tumors, Canc Hosp, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Bai, X.,Chen, Y.,Chen, Y.,et al. First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study[J]. ANNALS OF ONCOLOGY,2024,35.
APA Bai, X..,Chen, Y..,Chen, Y..,Liang, X..,Wang, H..,...&Liang, T..(2024).First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study.ANNALS OF ONCOLOGY,35.
MLA Bai, X.,et al."First-in- class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients (pts) with advanced solid tumors: First-in-human phase I study".ANNALS OF ONCOLOGY 35(2024).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。